Holocene Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Holocene Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.8M	Sell	160,991 -572,914	-78%	-$126M	0.09%	220
2026 Q1	$139M	Buy	733,905 +144,170	+24%	+$25.2M	0.33%	84
2025 Q4	$100M	Sell	589,735 -15,374	-3%	-$2.36M	0.21%	130
2025 Q3	$79.8M	Buy	605,109 +135,367	+29%	+$16.2M	0.18%	134
2025 Q2	$49.8M	Sell	469,742 -22,287	-5%	-$2.42M	0.12%	172
2025 Q1	$61.1M	Buy	+492,029	New	+$64.2M	0.18%	153
2021 Q2	–	Sell	-4,333	Closed	-$712K	–	886
2021 Q1	$712K	Sell	4,333 -667,236	-99%	-$110M	﹤0.01%	726
2020 Q4	$111M	Sell	671,569 -151,833	-18%	-$22.6M	0.7%	36
2020 Q3	$117M	Buy	823,402 +340,749	+71%	+$42.2M	0.89%	21
2020 Q2	$53.3M	Buy	482,653 +15,404	+3%	+$1.7M	0.47%	66
2020 Q1	$46.6M	Buy	467,249 +298,775	+177%	+$38.6M	0.5%	58
2019 Q4	$25.1M	Buy	+168,474	New	+$22.9M	0.23%	121
2018 Q2	–	Sell	-1,649	Closed	-$249K	–	642
2018 Q1	$249K	Sell	1,649 -3,072	-65%	-$451K	0.01%	448
2017 Q4	$636K	Buy	+4,721	New	+$655K	0.02%	338

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Holocene Advisors's JAZZ Position: Q2 2026 in Review

Holocene Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 78% in Q2 2026, selling an estimated $126M and leaving 160,991 shares worth $38.8M. The position accounts for 0.09% of the portfolio, ranked #220.

Holocene Advisors first reported a position in JAZZ in Q4 2017 and has held it in 14 quarters since. The position peaked at $139M in Q1 2026. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Holocene Advisors held 160,991 shares of Jazz Pharmaceuticals worth $38.8M as of Q2 2026.
Holocene Advisors sold 572,914 Jazz Pharmaceuticals shares in Q2 2026, an estimated $126M.
Jazz Pharmaceuticals made up 0.09% of Holocene Advisors's portfolio in Q2 2026, its #220 holding.
Holocene Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and has held it in 14 quarters since.
Holocene Advisors's Jazz Pharmaceuticals position peaked at $139M in Q1 2026.
643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.